WSJ Opinion: Potomac Watch Donald Trump's Order to Relax Marijuana Restrictions
Dec 19, 2025
The discussion centers on Trump's proposal to reclassify cannabis, shifting it from Schedule I to III, which could bolster marijuana businesses without legalizing recreational use. The hosts delve into the medical benefits and potential harms, noting increasing health risks linked to stronger cannabis. They also highlight rising daily usage and emergency room visits due to cannabis-related issues. Tensions between state legalization and federal laws are examined, along with the broader cultural and employment implications of changing cannabis policy.
AI Snips
Chapters
Transcript
Episode notes
Rescheduling Changes Classification Not Legality
- Rescheduling would move cannabis from Schedule I to Schedule III under the Controlled Substances Act.
- That change signals acknowledged medical use but does not legalize marijuana federally.
Big Financial Upside For Cannabis Firms
- Moving marijuana out of Schedule I would allow growers and retailers to deduct business expenses like other firms.
- Alicia Finley estimates this would deliver about $2 billion a year to cannabis companies and likely boost advertising or shareholder payouts.
Medical Benefits Evidence Is Limited
- Panelists argue evidence for broad medical benefits of cannabis is weak or insufficient.
- They warn rescheduling implies medical benefit despite unclear proof and high abuse risk.